Skip to main content
. 2017 Aug 25;66(11):2875–2887. doi: 10.2337/db17-0215

Figure 1.

Figure 1

Toxicity of 12/15-LOX inhibitors in mouse islets. A: Chemical structure of ML351 and caspase activity measurements performed with mouse islets in the presence of varying doses of ML351 for 24 h. B: Chemical structure of ML127 and caspase activity measurements performed with mouse islets in the presence of varying doses of ML127 for 24 h. C: Distribution of CANDOCK scores with the number of human proteins predicted to bind to ML127 and ML351. Scores less than a cutoff of −39.13 are predicted strong binders for both compounds. D: Number of predicted strong binders for ML127 and ML351 distribution in eight druggable protein classes. E: 12-HETE levels in media from mouse islets incubated with the indicated concentrations of ML351 and proinflammatory cytokines for 4 h. Data are mean ± SEM (n = 3 independent experiments). *P < 0.05 for the comparisons indicated. GPCR, G-protein–coupled receptor; RFU, relative fluorescence unit.